US Court Rejects Novartis’s Appeal in Whistleblower Case
New Jersey’s Superior Court, Appellate Division, has rejected Novartis’s appeal of a 2019 verdict in a case against a former executive turned whistleblower. Min Amy Guo, then executive director of the company’s health economics and outcomes research team, was fired in 2013 after expressing concerns that a cancer drug study would violate laws preventing kickbacks. She filed suit the following year and five years later a New Jersey court ruled Novartis was guilty of retaliation and must pay Guo $1.8 million in damages.
Biogen Settles MS Kickback Suit for $900M
Biogen has settled a whistleblower suit regarding kickbacks for its line of multiple sclerosis (MS) drugs. The company was sued for allegedly paying clinicians kickbacks when they prescribed its drugs Tecfidera, Tysabri, and Avonex. The settlement comes as competition from Novartis and Ocrevus closes in on Biogen’s MS drugs
